 DURHAM, N.C.--BUSINESS WIRE--Aerie Pharmaceuticals, Inc. NASDAQ: AERI, an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases, today announced that Casey C. Kopczynski, Ph.D., Chief Scientific Officer, will participate in a virtual panel discussion titled, What are the Greatest Unmet Needs Facing Ophthalmology Today?, at 